Impact of prolonged 48-H wireless capsule esophageal pH monitoring on diagnosis of gastroesophageal reflux disease and evaluation of the relationship between symptoms and reflux episodes;Impacto da monitorização prolongada do refluxo por pHmetria sem cateter por 48 horas, no diagnóstico da doença do refluxo gastroesofágico e no estudo da relação entre os sintomas e o refluxo

Arquivos de Gastroenterologia

Volumn 48, Issue 1, 2011, Pages 24-29

  Domingues, Gerson Ricardo de Souza ^a   Moraes Filho, Joaquim Prado P ^b   Domingues, Aline Gonçalves Leite ^a  

^a Lab de Motilidade Digestiva Imagem   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Capsule endoscopes; Esophageal pH monitoring; Gastric acidity determination; Gastroesophageal reflux

Indexed keywords

AMBULATORY MONITORING; ARTICLE; DIAGNOSTIC VALUE; ESOPHAGUS FOREIGN BODY; ESOPHAGUS PH; GASTROESOPHAGEAL REFLUX; HUMAN; PATIENT SAFETY; PH MEASUREMENT; SENSOR; THORAX PAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAPSULE ENDOSCOPY; ESOPHAGEAL PH MONITORING; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; MONITORING, AMBULATORY; RETROSPECTIVE STUDIES;

EID: 79956295228     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032011000100006     Document Type: Article

References (31)

1. Aanen MC, Bredenoord AJ, Numans ME, Samson M, Smout AJ. Reproducibility of symptom association analysis in ambulatory reflux monitoring. Am J Gastroenterol. 2008;103:2200-8.
2. Ayazi S, Lipham JC, Portale G, Peyre CG, Streets CG, Leers JM, Demeester SR, Banki F, Chan LS, Hagen JA, Demeester TR. Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. Clin Gastroenterol Hepatol. 2009;7:60-7.
3. Bortolotti M, Gatta L, Vakil N. Simultaneous esophageal pH recording with the Bravo system and a standard probe-based device. Gastroenterology. 2004;126(suppl 2):a320.
4. Campos GM, Peters JH, DeMeester TR, Oberg S, Crookes PF, Tan S, DeMeester SR, Hagen JA, Bremner CG. Multivariate analysis of factors prediciting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3:292-300.
5. Diaz S, Aymerich R, Clouse RE. The symptom association probability is superior to the symptom index for attributing symptoms to gastroesophageal reflux: validation using outcome from laparoscopic antireflux surgery. Gastroenterology. 2002;122(suppl):a75.
6. Fass R, Hell R, Sampliner RE, Pulliam G, Graver E, Hartz V, Johnson C, Jaffe P. Effect of ambulatory 24-hour esophageal pH monitoring on reflux-provoking activities. Dig Dis Sci. 1999;44:2263-9.
7. Galmiche JP, Clouse RE, Bálint A, Cook IJ, Kahrilas PJ, Paterson WG, Smout AJ. Functional esophageal disorders. Gastroenterology. 2006;130:1459-65.
8. Hirano I, Richter JE; Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668-85.
9. Hobson AR, Furlong PL, Aziz Q. Oesophageal afferent pathway sensitivity in non-erosive reflux disease. Neurogastroenterol Motil. 2008;20:877-83.
10. Hong RKS, Vaezi MF. Gastroesophageal reflux monitoring: pH (catheter and capsule) and impedance. Gastrointest Endosc Clin N Am. 2009;19:1-22.
11. Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci M. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992;87:1102-11.
12. Johnsson F, Joelsson B. Reproducibility of ambulatory oesophageal pH monitoring. Gut. 1988;29:886-9.
13. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 2008;359:1700-7
14. Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry: valuable tools in clinical and investigational esophagology. Gastroenterology. 2008;135:756-69.
15. Lacy BE, O'Shana T, Hynes M, Kelley MR Jr, Weiss JE, Paquette L, Rothstein RI. Safety and tolerability of transoral Bravo capsule placement after transnasal manometry using a validated conversion factor. Am J Gastroenterol. 2007;102:24-32.
16. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-56.
17. Moraes-Filho JP, Chinzon D, Eisig JN, Hashimoto CL, Zaterka S. Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population. Arq Gastroenterol. 2005;42:122-7.
18. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol. 2003;98:740-9.
19. Pandolfino JE, Bianchi LK, Lee TJ, Hirano I, Kahrilas PJ. Esophagogastric junction morphology predicts susceptibility to exercise-induced reflux. Am J Gastroenterol. 2004;99:1430-6.
20. Pandolfino JE. Bravo capsule pH monitoring. Am J Gastroenterol. 2005;100: 8-10.
21. Pandolfino JE, Kahrilas PJ. Prolonged pH monitoring: Bravo capsule. Gastrointest Endosc Clin N Am. 2005;15:307-18.
22. Pandolfino JE, Lee TJ, Schreiner MA, Zhang Q, Roth MP, Kahrilas PJ. Comparison of esophageal acid exposure at 1 cm and 6 cm above the squamocolumnar junction using the Bravo pH monitoring system. Dis Esophagus. 2006;19:177-82.
23. Pohl D, Tutuian R. Reflux monitoring: pH-metry, bilitec and oesophageal impedance measurements. Best Pract Res Clin Gastroenterol. 2009;23:299-311.
24. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluationg gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3:329-34.
25. Pritchett JM, Aslam J, Slaughter C, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol. 2009;7:743-8.
26. Remes-Troche JM, Ibarra-Palomino J, Carmona-Sánchez RI, Valdovinos MA. Performance, tolerability, and symptoms related to prolonged pH monitoring using the Bravo system in Mexico. Am J Gastroenterol. 2005;100:2382-6.
27. Sweis R, Fox M, Anggiansah R, Anggiansah A, Basavaraju K, Canavan R, Wong T. Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies. Aliment Pharmacol Ther. 2009;29:669-76.
28. seng D, Rizvi AZ, Fennerty B, Jobe BA, Diggs BS, Sheppard BC, Gross SC, Swanstrom LL, White NB, Aye RW, Hunter JG. Forty-eight-hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg. 2005;9:1043-52.
29. Wenner J, Johnsson F, Johansson J, Oberg S. Wireless oesophageal pH monitoring: feasibility, safety and normal values in healthy subjects. Scand J Gastroenterol. 2005;40:768-74.
30. Wenner J, Johnsson F, Johnsson J, Oberg S. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102:239-45.
31. Wong WM, Bautista J, Dekel R, Malagon IB, Tuchinsky I, Green C, Dickman R, Esquivel R, Fass R. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24h oesophageal pH monitoring-a randomized trial. Aliment Pharmacol Ther. 2005;21:155-63.